※下線付の著者:当社研究員

原著論文・総論・著書

  1. Uchida K T. Waste Clearance in the Brain and Neuroinflammation: A Novel Perspective on Biomarker and Drug Target Discovery in Alzheimer’s Disease. Cells,11(5); 919; 2022
  2. Nakamura S, Yomota S, Ito H, Akinaga N, Hori A, Chinomi K, Suzuki H, Uchida K, and Asada T. A Novel Cognitive Function Scale Using Functional Near-Infrared Spectroscopy for Evaluating Cognitive Dysfunction. J Alzheimers Dis. 81:1579-1588, 2021.
  3. Ide M, Ohnishi T, Toyoshima M, Meno K, Uchida K, et al. Excess hydrogen sulfide and polysulfides production underlies a schizophrenia pathophysiology. EMBO Mol Med, 11:e10695, 2019.
  4. Shan L, Suzuki H, Ito H, Korenaga T, Akatsu H, Meno K, and Uchida K. Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment. Alzheimers Dement (Amst), 11:85-97, 2019.
  5. Uchida K, Shan L, Suzuki H, Tabuse Y, Nishimura Y, Hirokawa Y, Mizukami K, Akatsu H, Meno K, and Asada T. Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline. Alzheimers Dement (Amst) 1:270-280, 2015.
  6. 鈴木秀昭.認知症の早期発見・介入に役立つMCIのリスク評価(解説論文).日本早期認知症学会誌. 13:26-35, 2020.
  7. 内田和彦.MCIスクリーニング検査の開発.新井平伊(監修)アルツハイマー病-発症メカニズムと新規診断法・創薬・治療開発 エヌティーエス pp.191-199, 2018
  8. 内田和彦.MCIと認知症の血液バイオマーカーの現状と展望.老年精神医学雑誌, 29:90-98. 2018.
  9. 内田和彦, 鈴木秀昭.MCIおよびプレクリニカルADの血液バイオマーカーへの期待.臨床検査, 60: 1530-1536, 2016.
  10. 内田和彦.MCIとプレクリニカルADの血液・髄液バイオマーカーとその病態生理学的背景.老年精神医学雑誌, 27: 631-639, 2016

国際学会Proceedings

  1. Inoue M, Ito H, Shan L, Suzuki H, Uchida K, et al. Identification of plasma protein panels for detection of cognitive decline in MCI and AD by LC-MS/MS. Alzheimers Dement, AAIC 2021.
  2. Ito H, Shan L, Hata N, Korenaga T, Suzuki H, Meno K, Uchida K, et al. Plasma Aβ40, Aβ42 and Aβ-clearance proteins as blood biomarkers for Alzheimer’s disease, subjective cognitive decline, and MCI. Alzheimers Dement, AAIC 2021.
  3. Uchida K, et al. Altered serum levels of proteins involved in beta-amyloid clearance in the aftermath of the Kumamoto magnitude 7.3 earthquake. Alzheimers Dement, 16 (Suppl. 5):e045682, 2020.
  4. Liu S, Ito H, Ogawa N, Akatsu A, and Uchida K. Plasma Aβ in cerebral microbleeds-positive subjects with cognitive impairment. Alzheimers Dement, 16 (Suppl. 5):e045665, 2020.
  5. Sato T, Uchida K, Tanaka M, Itai Y, Takahashi N, Tanaka M, Yoshida A, Oniki K, Suzuki H, Osame M. Reduced level of proteins involved ㏌ Aβ clearance ㏌ serum followed by atrophy of the medial temporal structures in the aftermath of the earthquake. Alzheimers Dement, 15:P334, 2019.
  6. Suzuki H, Uchida K, Ito H, Nishimura Y, T Korenaga, Akatsu H, Matsukawa M, Arai T, Meno K, and Asada T. Peripheral profiles of complement proteins are potential biomarkers for mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement, 13:714-715, 2017.
  7. Meno K, Suzuki H, Ito H, Nishimura Y, Akatsu H, Matsukawa M, Arai T, Matsubara T, Kawakami K, Nakamura S, Asada T, and Uchida K. Development of a novel blood-based diagnostic system for mild cognitive impairment and Alzheimer’s disease using circulating peptides. Alzheimers Dement, 13:359-360, 2017.
  8. Yomota S, Nakata H, Suzuki H, Uchida K, Ando E, Nakamura S, and Asada T. Investigation of a task for early detection of cognitive decline in elderly people using functional near-infrared spectroscopy (fNIRS) for diagnosis of Alzheimer’s disease. Alzheimers Dement, 13:1381-1382, 2017.
  9. Shan L, Uchida K, Suzuki H, Tabuse Y, Nishimura Y, Hirokawa Y, Mizukami K, Akatsu H, Meno K, and Asada T. Association of amyloid-β sequester proteins in serum with cognitive decline, brain atrophy, and cerebral blood flow. Alzheimers Dement, 12:358, 2016.

その他

  1. 西道隆臣,樋口真人,内田和彦,ジョン・ハーディー.脳とは何か – アルツハイマー病研究最前線.ニュートン別冊 2019年12月5日発行
  2. 内田和彦,伊東大介.アルツハイマー病の早期発見・早期治療に挑む – 新しい血液検査でアルツハイマー病の予備群を判定できるようになった.ニュートン2016年1月号
  3. 紹介記事 血液検査で早期にわかる軽度認知障害のリスク : 認知症への移行を防ぐ予防プログラムも実施 日経ヘルス 217:85, 2015

国内学会発表

  1. 井上 真, 目野 浩二, 鈴木秀昭, 伊藤 ひとみ, 劉 珊, 松川 則之, 朝田 隆, 新井 哲明, 内田 和彦.軽度認知障害(MCI)およびアルツハイマー病のための血漿タンパク質LC-MS/MSスクリーニング検査の開発. 第62回日本人間ドック学会学術集会. 2021
  2. 伊藤ひとみ劉 珊畑 直子,赤津裕康,松川則之,朝田隆,新井哲明,内田和彦 血漿を用いたMCIスクリーニング検査とAβ40/42のアルツハイマー病とMCI診断における臨床有効性について. 第61回日本人間ドック学会学術集会. 2020
  3. Ito H, Shan L, Hata N, Dewaele K, Stoops E, Brix B, Akatsu A, Matsukawa N, Asada T, Arai T, and Uchida K. Plasma Aβ42/40 and Aβ clearance proteins as blood biomarkers for MCI and AD. 第39回日本認知症学会学術集会. 2020
  4. Ito H, Shan L, Hata N, Akatsu A, Matsukawa N, Asada T, Arai T, and Uchida K. Plasma Aβ40, Aβ42 and Aβ clearance proteins as blood biomarkers for Alzheimer’s disease (AD) and MCI. the Joint Meeting of the 27th International Health Evaluation and Promotion Association and the 4th World Congress on Ningen Dock. 2020
研究内容・分野 論文・学会 特許・知財

HTML5のcanvas要素、またはexlorer canvasに対応のブラウザでご覧下さい。